Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $9.16 in the prior trading day, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $9.36, up 2.18%. In other words, the price has increased by $2.18 from its previous closing price. On the day, 1.6 million shares were traded. ARQT stock price reached its highest trading level at $9.3691 during the session, while it also had its lowest trading level at $9.05.
Ratios:
Our goal is to gain a better understanding of ARQT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.19 and its Current Ratio is at 8.46. In the meantime, Its Debt-to-Equity ratio is 1.11 whereas as Long-Term Debt/Eq ratio is at 1.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on August 28, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On January 03, 2024, Mizuho Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $8.
Mizuho Downgraded its Buy to Neutral on October 26, 2023, whereas the target price for the stock was revised from $57 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 24 ’24 when Topper David Joseph sold 11,626 shares for $9.48 per share. The transaction valued at 110,264 led to the insider holds 158,374 shares of the business.
Topper David Joseph bought 11,626 shares of ARQT for $110,264 on Sep 24 ’24. On Sep 03 ’24, another insider, Welgus Howard G., who serves as the Director of the company, sold 10,000 shares for $10.77 each. As a result, the insider received 107,695 and left with 191,944 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1094099712 and an Enterprise Value of 939225984. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.28 while its Price-to-Book (P/B) ratio in mrq is 5.85. Its current Enterprise Value per Revenue stands at 7.112 whereas that against EBITDA is -5.268.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $13.17, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is -4.61%, while the 200-Day Moving Average is calculated to be 11.75%.
Shares Statistics:
The stock has traded on average 2.34M shares per day over the past 3-months and 2314690 shares per day over the last 10 days, according to various share statistics. A total of 116.89M shares are outstanding, with a floating share count of 101.35M. Insiders hold about 13.25% of the company’s shares, while institutions hold 99.47% stake in the company. Shares short for ARQT as of 1726185600 were 24863988 with a Short Ratio of 10.64, compared to 1723680000 on 23804159. Therefore, it implies a Short% of Shares Outstanding of 24863988 and a Short% of Float of 26.319999.
